ArticleHIV medicine2026
Prior PrEP use and discontinuation in individuals newly diagnosed with HIV.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn settings with high uptake of HIV pre-exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
methodsWe conducted a retrospective case-note review of individuals newly diagnosed with HIV at 56 Dean Street, London, UK, between 1 January 2017 and 31 December 2024. Data collected included demographics, prior PrEP use, adherence and reasons for discontinuation and baseline blood results. Individuals with prior PrEP use were compared with those who had never used PrEP.
resultsAmong 1080 individuals newly diagnosed with HIV, 210 (19.4%) reported prior PrEP use. The annual proportion with prior PrEP use increased from 4.3% in 2017 to 60.5% in 2024. Compared with never-PrEP users, those with prior PrEP use were more likely to have recently acquired HIV (85.7% vs. 58.2%, p < 0.00001), to have previously attended the clinic (70.0% vs. 37.7%, p < 0.00001) and to have undergone more frequent HIV testing. Among prior PrEP users, 36.2% reported PrEP discontinuation, and in those who had not discontinued PrEP at diagnosis, 73.5% reported poor adherence. The most common reasons for discontinuation were lack of PrEP supply, monogamy and gastrointestinal side effects. The only major resistance mutation that showed a significant difference between the two groups was M184I/V: 27 (19.6%) in PrEP-exposed versus 7 (0.8%) in not-PrEP-exposed.
conclusionsIn this high-PrEP-uptake setting, a growing proportion of individuals newly diagnosed with HIV report prior PrEP use, most commonly characterized by discontinuation or suboptimal adherence. These findings highlight an ongoing unmet need for interventions that support PrEP persistence and continuity, including improved access pathways and alternative PrEP formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.